Fabry Disease, a rare genetic disorder caused by the deficiency of the enzyme alpha-galactosidase A, leads to the accumulation of globotriaosylceramide in various tissues, resulting in a range of debilitating symptoms. The market for Fabry Disease drugs has seen significant advancements in recent years, driven by increasing awareness, diagnostic improvements, and innovative therapeutic...